Skip to main content

Advertisement

Log in

Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab

  • Case Report
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Anti-CTLA-4 antibodies are human monoclonal antibodies previously studied in the treatment of metastatic melanoma (MM). CTLA-4 is an inhibitory receptor on cytotoxic T cells, blockade of which will activate T cells allowing them to attack malignant cells. Normal host cells may also be affected, and immune-mediated enterocolitis can occur. This is a prospective observational study on the use of corticosteroids and infliximab in the treatment of patients with immune-mediated colitis secondary to anti-CTLA-4 antibody treatment of MM. Five patients presented with colitis after medication administration. Patients were treated with high-dose corticosteroids for 1 week, but diarrhea did not completely abate in any of them. They were then treated successfully with infliximab. One patient had recurrence of symptoms and responded to repeat treatment with infliximab. Patients who develop immune-mediated colitis after administration of anti-CTLA-4 antibodies have previously been reported to respond to corticosteroids, but in our study, all required treatment with infliximab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283–2289. doi:10.1200/JCO.2005.04.5716.

    Article  PubMed  CAS  Google Scholar 

  2. Reuben JM, Lee BN, Li C, et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006;106:2437–2444. doi:10.1002/cncr.21854.

    Article  PubMed  CAS  Google Scholar 

  3. Pfizer announces discontinuation of phase III clinical trial for patients with advanced melanoma. Business Wire. 2008.

  4. Medarex, Bristol-Myers delay BLA submission for ipilimumab; FDA seeks more data. Thomson Financial News. 2008.

  5. Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–413. doi:10.1016/1074-7613(94)90071-X.

    Article  PubMed  CAS  Google Scholar 

  6. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459–465. doi:10.1084/jem.182.2.459.

    Article  PubMed  CAS  Google Scholar 

  7. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med. 1996;183:2533–2540. doi:10.1084/jem.183.6.2533.

    Article  PubMed  CAS  Google Scholar 

  8. Chambers CA, Krummel MF, Boitel B, et al. The role of CTLA-4 in the regulation and initiation of T-cell responses. Immunol Rev. 1996;153:27–46. doi:10.1111/j.1600-065X.1996.tb00919.x.

    Article  PubMed  CAS  Google Scholar 

  9. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712–4717. doi:10.1073/pnas.0830997100.

    Article  PubMed  CAS  Google Scholar 

  10. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by CTLA-4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–8377. doi:10.1073/pnas.1533209100.

    Article  PubMed  CAS  Google Scholar 

  11. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741–750. doi:10.1200/JCO.2005.01.128.

    Article  PubMed  CAS  Google Scholar 

  12. Keler T, Halk E, Vitale L, et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J Immunol. 2003;171:6251–6259.

    PubMed  CAS  Google Scholar 

  13. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053. doi:10.1200/JCO.2005.06.205.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. S. Barkin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Johnston, R.L., Lutzky, J., Chodhry, A. et al. Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab. Dig Dis Sci 54, 2538–2540 (2009). https://doi.org/10.1007/s10620-008-0641-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-008-0641-z

Keywords

Navigation